LipoScience Names Timothy J. Fischer Chief Operating Officer
News Jan 30, 2012
“In a very short time, Tim has helped shape our corporate strategy and our culture. He has enhanced our ability to effectively achieve our goals with the collective effort of cross-functional teams,” said Richard O. Brajer, Chief Executive Officer of LipoScience. “His leadership will be essential in achieving our core strategies of market conversion, platform expansion and changing the clinical standard of care.”
With more than 25 years of experience, Mr. Fischer is a recognized leader in the in vitro diagnostics industry. He has extensive familiarity in the design, development and commercialization of over 90 products in the fields of hematology, oncology and pathology. Prior to joining LipoScience, Mr. Fischer most recently served as Vice President of Development for the women’s health and cancer business at Becton Dickinson. During his career, he has been granted more than 35 patents, has authored numerous publications and has successfully brought several novel technologies and assays to the clinical market. Mr. Fischer has a Bachelor of Science degree in Biology from Indiana University.
Mr. Fischer added, “Our flagship product, the NMR LipoProfile® test, will potentially drive a paradigm shift in cardiovascular management and treatment and our technology platform may pave the way for a new generation of fully automated clinical metabolomic assays. I am excited to help lead this important effort.”
The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019